Amylyx Pharmaceuticals Inc
(NAS:AMLX)
$
19.73
+0.18 (+0.95%)
Market Cap: 2.19 Bil
Enterprise Value: 1.92 Bil
PE Ratio: 0
PB Ratio: 8.02
GF Score: 33/100 Amylyx Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript
Dec 03, 2025 / 09:00PM GMT
Release Date Price:
$14.21
(+3.35%)
Geoffrey Meacham
Citi Infrastructure Investments LLC - Analyst
All right. Okay, welcome to the Citi Global Healthcare Conference.
I'm Geoff Meacham. I'm the Global Head of Healthcare; and senior analyst in SMID Cap, biotech, and pharma. Obviously, Jarwei Fang is up here with me from my team.
We're thrilled to have Amylyx. So Justin Klee is with us, Co-CEO. We won't trash the other Co-CEO. You got to look to Miami.
Justin Klee
Amylyx Pharmaceuticals Corp - Co-Chief Executive Officer, Co-Founder, Director
Yes. Yes, exactly. Yes.
Geoffrey Meacham
Citi Infrastructure Investments LLC - Analyst
We also have Jim Frates, CFO, in the crowd here. Yes, Justin, do you want to just give a bit of a two-minute drill, and we get into some questions. How about that?
Justin Klee
Amylyx Pharmaceuticals Corp - Co-Chief Executive Officer, Co-Founder, Director
Sure. Yes, very happy to. And yes, my fellow Co-CEO, Co-Founder, Josh, is out at the ALS conference in San
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot